Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine

AIDS

Volumn 25, Issue 1, 2011, Pages 27-36

  Papagno, Laura ^a,b   Alter, Galit ^c   Assoumou, Lambert ^a,b   Murphy, Robert L ^d   Garcia, Felipe ^e   Clotet, Bonaventura ^f   Larsen, Martin ^a,b   Braibant, Martine ^g   Marcelin, Anne Geneviève ^a,b,h   Costagliola, Dominique ^a,b,i   Altfeld, Marcus ^c   Katlama, Christine ^a,b,i   Autran, Brigitte ^a,b,j  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f Irsi Caixa Foundation   (Spain)

^g UNIVERSITÉ DE TOURS   (France)

^h Virology Laboratory   (France)

ⁱ Tropical and Infectious Diseases Department   (France)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; INTERFERON PRODUCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; CANARYPOX VIRUS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VIRAL LOAD; VIRAL VACCINES;

EID: 78650311033     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328340fe55     Document Type: Article

References (33)

1. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305:205-208.
2. Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meif-fredy V, Venet A, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses 2007; 23:1105-1113.
3. Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-617.
4. MarkowitzM,Jin X,Hurley A, Simon V, Ramratnam B,Louie M, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-643. (Pubitemid 34925535)
5. Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 2006; 194:1672-1676.
6. Levy Y, Durier C, Lascaux AS, Meiffredy V, Gahery-Segard H, Goujard C, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-413.
7. Tubiana R, Carcelain G, Vray M, Gourlain K, Dalban C, Cher-mak A, et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 2005; 23:4292-4301.
8. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22:1313-1322.
9. Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334:1222-1230.
10. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, Feinberg MB. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182:1727-1737.
11. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002; 20 (Suppl. 5):B29-B32.
12. Jin X, Ramanathan M Jr, Barsoum S, Deschenes GR, Ba L, Binley J, et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 2002; 76:2206-2216.
13. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
14. TartagliaJ,Excler JL,ElHabib R,LimbachK,Meignier B,Plotkin S, KleinM.Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 1998; 14 (Suppl. 3):S291-S298.
15. Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, Theodorou I, et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis 2005; 191:2053-2063.
16. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-96.
17. R T cells through the combination of MHC class I tetramer and intracellular staining. J Immunol Methods 2002; 268:9-19.
18. R T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78.
19. Barin F, Brunet S, Brand D, Moog C, Peyre R, Damond F, et al. Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 core-ceptors. J Infect Dis 2004; 189:322-327.
20. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, Katinger H, et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term nonprogressors: prevalence and association with neutralizing activity. AIDS 2006; 20:1923-1930.
21. Dalmasso C, Broet P, Moreau T. [Multiple comparison procedures: principles, limits. Applications to microarray pheno-type-genotype analysis]. Rev Epidemiol Sante Publique 2004; 52:523-537.
22. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, Buchbinder S, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med 2005; 11:1290-1292.
23. R T cells. Blood 2006; 107:4781-4789.
24. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-850.
25. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-258.
26. R T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8:379-385.
27. R T cells. J Exp Med 1997; 186:1407-1418.
28. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-712.
29. Gunthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000; 181:522-531.
30. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998; 177:1230-1246.
31. R cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999; 180:290-298.
32. R T cell responses. Eur J Immunol 2006; 36:2585-2594.
33. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300:337-339.